Drug · Small Molecule

Telmisartan

CI-DRUG-00000582Explore in graph →NCIt C47746 CHEMBL1017 CIViC Approved

Regulatory

Approvals (1)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

openfdaRegulatory1 approval record · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
US FDA	—	Telmisartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.	approved	Jan 8, 2014	openfda

Data updated 17 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 2	3	2	4	1	US	Jan 8, 2014	Apr 9, 2020
Malignant Breast Neoplasm	Phase2	Phase 2	1	0	1	0	—	—	2026-02
Malignant Ovarian Neoplasm	Phase2	Phase 2	1	1	1	0	—	—	Jan 21, 2026
Malignant Prostate Neoplasm	Phase1	Phase 1	1	1	1	0	—

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ATP7B Expression1
Telmisartan	Malignant Ovarian Neoplasm

Clinical trials

Trials with this intervention (5)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–5 of 5 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06168487	Telmisartan in Prostate Cancer	recruiting	Phase 1	36	Tyler J CurielOTHER	1	Jul 22, 2026	clinicaltrials
NCT07370506	Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients	not yet recruiting	Phase 1 / Phase 2	36	Tanta University

Molecule

Record

Kind: Small Molecule
Mechanism: Type-1 angiotensin II receptor antagonist
Targets: 1 gene
UNII: U5SYW473RQ
Aliases: (1,1'-Biphenyl)-2-carboxylic Acid, 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-, 4'-((4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic Acid, BIBR 277, BIBR-277, Bibr-277se, BIBR 277 SE, C09CA07, Kinzalmono, Kinzalmono (previously telmisartan boehringer ingelheim pharma kg), Micardis, Pritor, Semintra, Telmisartan, Telmisartan actavis, Telmisartan component of kinzalkomb, Telmisartan component of micardis hct, Telmisartan component of micardisplus, Telmisartan component of onduarp, Telmisartan component of pritorplus, Telmisartan component of tolucombi, Telmisartan component of twynsta, Telmisartan teva, Telmisartan teva pharma, Tolura

Data updated 20 hours agoSource updated unknown

Identifiers

Codes (0)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

Data not yet available

No cross-reference code recorded yet beyond the record identifiers above.

Regulatory status is jurisdiction-specific and time-bound. Nothing on this page is a treatment recommendation.